GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWOBY) » Definitions » Common Stock

SWOBY (Swedish Orphan Biovitrum AB) Common Stock : $18 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Swedish Orphan Biovitrum AB Common Stock?

Swedish Orphan Biovitrum AB's quarterly common stock increased from Jun. 2024 ($18 Mil) to Sep. 2024 ($19 Mil) but then declined from Sep. 2024 ($19 Mil) to Dec. 2024 ($18 Mil).

Swedish Orphan Biovitrum AB's annual common stock increased from Dec. 2022 ($16 Mil) to Dec. 2023 ($19 Mil) but then declined from Dec. 2023 ($19 Mil) to Dec. 2024 ($18 Mil).

Swedish Orphan Biovitrum AB Common Stock Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Common Stock Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.97 18.59 16.38 18.91 17.75

Swedish Orphan Biovitrum AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.91 18.63 18.50 19.06 17.75

Swedish Orphan Biovitrum AB Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Swedish Orphan Biovitrum AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWOBY) » Definitions » Common Stock
Comparable Companies
OSTO:BIOG B OSTO:SECARE OSTO:EQL OSTO:CRNO B OSTO:ENZY OSTO:DICOT OSTO:CINPHA OSTO:ORX OSTO:MOB OSTO:KLAR ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
BIOVF:USA SOBI:Sweden SOBIs:UK 0MTD:UK B6E:Germany
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Website
https://www.sobi.com
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).